Tizanidine hydrochloride (BioDeep_00000719860)

   

Chemicals and Drugs


代谢物信息卡片


Tizanidine hydrochloride

化学式: C9H9Cl2N5S (288.9955694)
中文名称: 盐酸替扎尼定
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl
InChI: 1H

描述信息

D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
D002491 - Central Nervous System Agents > D000700 - Analgesics
Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons. Target: α2-adrenergic receptor Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, ALS, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant. It is also prescribed for some symptoms of fibromyalgia. Tizanidine has been found to be as effective as other antispasmodic drugs and has superior tolerability to that of baclofen and diazepam. Tizanidine can be very strong even at the 2 mg dose and may cause hypotension, so caution is advised when it is used in patients who have a history of orthostatic hypotension, or when switching from gel cap to tablet form and vice versa. Tizanidine can occasionally cause liver damage, generally the hepatocellular type. Clinical trials show that up to 5\% of patients treated with tizanidine had elevated liver function test values, though symptoms disappeared upon withdrawal of the drug. Care should be used when first beginning treatment with tizanidine with regular liver tests for the first 6 months of treatment.

同义名列表

2 个代谢物同义名

Tizanidine hydrochloride; Tizanidine (hydrochloride)



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hetal Thakkar, Bhumi Modi, Brijesh Patel. Intranasal spray of cubosomal tizanidine hydrochloride for brain targeting: in vitro and in vivo characterisation. Journal of microencapsulation. 2023 Dec; 40(5):366-383. doi: 10.1080/02652048.2023.2209651. [PMID: 37129532]
  • Mian Zhang, Ciarán Fisher, Iain Gardner, Xian Pan, Peter Kilford, Frederic Y Bois, Masoud Jamei. Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework. Drug metabolism and disposition: the biological fate of chemicals. 2022 07; 50(7):957-967. doi: 10.1124/dmd.121.000818. [PMID: 35504655]
  • Theodoros V Giannouchos, Ainhoa Gómez-Lumbreras, Daniel C Malone. Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S. The American journal of emergency medicine. 2022 05; 55(?):147-151. doi: 10.1016/j.ajem.2022.03.008. [PMID: 35325788]
  • Leonna Dsouza, Pinal Chaudhari, Bheemisetty Brahmam, Shaila A Lewis. Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2021 Oct; 165(?):105920. doi: 10.1016/j.ejps.2021.105920. [PMID: 34192586]
  • Michael J Brucculeri, Juan Garcia. Potassium wasting nephropathy in the setting of tizanidine overdose: a case report. Journal of medical case reports. 2021 May; 15(1):250. doi: 10.1186/s13256-021-02811-8. [PMID: 33931107]
  • Bhuvanenthiran Mutharani, Palraj Ranganathan, Tse-Wei Chen, Shen-Ming Chen, Jeyaraj Vinoth Kumar. Thermoreversible Switchlike Electrocatalytic Reduction of Tizanidine Based on a Graphene Oxide Tethered Stimuli-Responsive Smart Surface Supported Pd Catalyst. Analytical chemistry. 2020 07; 92(13):8965-8973. doi: 10.1021/acs.analchem.0c00958. [PMID: 32436691]
  • Weijiang Zhang, Christine McIntyre, Todd Riehl, Harper Forbes, Enric Bertran, Hye Jin Choi, Dae Ho Lee, Jeeyun Lee. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies. Clinical pharmacology in drug development. 2020 07; 9(5):651-658. doi: 10.1002/cpdd.788. [PMID: 32311241]
  • Hetal Thakkar, Kartik Pandya, Brijesh Patel. Microneedle-Mediated Transdermal Delivery of Tizanidine Hydrochloride. Methods in molecular biology (Clifton, N.J.). 2020; 2059(?):239-258. doi: 10.1007/978-1-4939-9798-5_13. [PMID: 31435926]
  • Fathalla Belal, Mahmoud A Omar, Sayed Derayea, Mohamed A Hammad, Sahar Zayed, Safaa F Saleh. Simultaneous Determination of Tizanidine, Nimesulide, Aceclofenac and Paracetamol in Tablets and Biological Fluids Using Micellar Liquid Chromatography. Journal of chromatographic science. 2018 Mar; 56(3):233-241. doi: 10.1093/chromsci/bmx105. [PMID: 29236980]
  • C W Locuson, P Williams, J M Adcock, J S Daniels. Evaluation of tizanidine as a marker of canine CYP1A2 activity. Journal of veterinary pharmacology and therapeutics. 2016 Apr; 39(2):122-30. doi: 10.1111/jvp.12256. [PMID: 26228837]
  • Golaleh Sheykhaghaei, Moayad Hossainisadr, Salah Khanahmadzadeh, Mirabdollah Seyedsajadi, Awat Alipouramjad. Magnetic molecularly imprinted polymer nanoparticles for selective solid phase extraction and pre-concentration of Tizanidine in human urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 Feb; 1011(?):1-5. doi: 10.1016/j.jchromb.2015.12.013. [PMID: 26744788]
  • Michael Haupts, Carlos Vila, Anna Jonas, Kerstin Witte, Lourdes Álvarez-Ossorio. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. European neurology. 2016; 75(5-6):236-43. doi: 10.1159/000445943. [PMID: 27160412]
  • Naoya Miura, Takeshi Saito, Takayuki Taira, Takeshi Yamagiwa, Sein Morita, Sadaki Inokuchi. Rapid simultaneous determination of eperisone, tolperisone, and tizanidine in human serum by using a MonoSpin® C18 extraction column and liquid chromatography/tandem mass spectrometry. Journal of AOAC International. 2014 Nov; 97(6):1546-51. doi: 10.5740/jaoacint.13-295. [PMID: 25632432]
  • Daniela Cristina Vitale, Cateno Piazza, Tiziana Sinagra, Vincenzo Urso, Francesco Cardì, Filippo Drago, Salvatore Salomone. Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. Clinical drug investigation. 2013 Dec; 33(12):885-91. doi: 10.1007/s40261-013-0137-2. [PMID: 24085590]
  • Mutasim Al-Ghazawi, Mamoun Alzoubi, Bashar Faidi. Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. International journal of clinical pharmacology and therapeutics. 2013 Mar; 51(3):255-62. doi: 10.5414/cp201790. [PMID: 23380428]
  • Sevgi Tatar Ulu. Sensitive spectrofluorimetric determination of tizanidine in pharmaceutical preparations, human plasma and urine through derivatization with dansyl chloride. Luminescence : the journal of biological and chemical luminescence. 2012 Sep; 27(5):426-30. doi: 10.1002/bio.1367. [PMID: 23044773]
  • Ahmed S El-Hefnawy, Tamer Helmy, Mohamed M El-Assmy, Osama Sarhan, Ashraf T Hafez, Mohammed Dawaba. Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. Urology. 2012 Feb; 79(2):428-33. doi: 10.1016/j.urology.2011.10.043. [PMID: 22196407]
  • Farhan Ahmed Siddiqui, M Saeed Arayne, Najma Sultana, Faiza Qureshi. Development and validation of stability-indicating HPLC method for the simultaneous determination of paracetamol, tizanidine, and diclofenac in pharmaceuticals and human serum. Journal of AOAC International. 2011 Jan; 94(1):150-8. doi: . [PMID: 21391492]
  • Susan W Publow, Donald L Branam. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010 Oct; 67(19):1606-10. doi: 10.2146/ajhp090657. [PMID: 20852161]
  • Shujaat A Khan, Mahmood Ahmad, Ghulam Murtaza, Muhammad N Aamir, Naveed Akhtar, Rozina Kousar. Formulation of two-drug controlled release non-biodegradable microparticles for potential treatment of muscles pain and spasm and their simultaneous spectrophotometeric estimation. Acta poloniae pharmaceutica. 2010 May; 67(3):299-306. doi: . [PMID: 20524433]
  • Kenji Momo, Masato Homma, Yoshiko Osaka, Shin-ichi Inomata, Makoto Tanaka, Yukinao Kohda. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. Journal of clinical pharmacology. 2010 Mar; 50(3):331-7. doi: 10.1177/0091270009341961. [PMID: 19789372]
  • Herbert R Henney, Anthony Fitzpatrick, Johnston Stewart, Jacob D Runyan. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects. Clinical therapeutics. 2008 Dec; 30(12):2263-71. doi: 10.1016/j.clinthera.2008.12.014. [PMID: 19167586]
  • Marjo J Karjalainen, Pertti J Neuvonen, Janne T Backman. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. European journal of clinical pharmacology. 2008 May; 64(5):511-9. doi: 10.1007/s00228-007-0456-4. [PMID: 18197403]
  • H R Henney, J D Runyan. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. International journal of clinical practice. 2008 Feb; 62(2):314-24. doi: 10.1111/j.1742-1241.2007.01660.x. [PMID: 18199279]
  • Janne T Backman, Marika T Schröder, Pertti J Neuvonen. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. European journal of clinical pharmacology. 2008 Jan; 64(1):17-24. doi: 10.1007/s00228-007-0389-y. [PMID: 17955229]
  • Marjo J Karjalainen, Pertti J Neuvonen, Janne T Backman. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. European journal of clinical pharmacology. 2007 Sep; 63(9):829-36. doi: 10.1007/s00228-007-0335-z. [PMID: 17618427]
  • J J Lilja, J T Backman, P J Neuvonen. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clinical pharmacology and therapeutics. 2007 Jun; 81(6):833-9. doi: 10.1038/sj.clpt.6100149. [PMID: 17392729]
  • Herbert R Henney, Jaymin Shah. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Clinical therapeutics. 2007 Apr; 29(4):661-9. doi: 10.1016/j.clinthera.2007.04.012. [PMID: 17617289]
  • Jaymin Shah, Keith A Wesnes, Rosemary A Kovelesky, Herbert R Henney. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clinical therapeutics. 2006 Sep; 28(9):1308-17. doi: 10.1016/j.clinthera.2006.09.014. [PMID: 17062304]
  • Janne T Backman, Marjo J Karjalainen, Mikko Neuvonen, Jouko Laitila, Pertti J Neuvonen. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. British journal of clinical pharmacology. 2006 Sep; 62(3):345-57. doi: 10.1111/j.1365-2125.2006.02653.x. [PMID: 16934051]
  • K Dashora, S Saraf, Swarnlata Saraf. In-vitro studies of tizanidine controlled-release microcapsular matrices. Pakistan journal of pharmaceutical sciences. 2006 Jul; 19(3):177-81. doi: NULL. [PMID: 16935822]
  • Janne T Backman, Marika T Granfors, Pertti J Neuvonen. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. European journal of clinical pharmacology. 2006 Jun; 62(6):451-61. doi: 10.1007/s00228-006-0127-x. [PMID: 16758262]
  • Ramakrishna V S Nirogi, Vishwottam N Kandikere, Manoj Shukla, Koteshwara Mudigonda, Santosh Maurya. Quantification of tizanidine in human plasma by liquid chromatography coupled to tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2006; 20(15):2286-92. doi: 10.1002/rcm.2592. [PMID: 16810637]
  • Marika T Granfors, Janne T Backman, Jouko Laitila, Pertti J Neuvonen. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clinical pharmacology and therapeutics. 2005 Oct; 78(4):400-11. doi: 10.1016/j.clpt.2005.06.009. [PMID: 16198659]
  • Yukiko Kitabata, Hikari Orita, Motohiro Kamimura, Kazuhiro Shiizaki, Nobuhiko Narukawa, Takaya Abe, Hirotsugu Kobata, Tadao Akizawa. Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2005 Feb; 9(1):74-7. doi: 10.1111/j.1774-9987.2005.00206.x. [PMID: 15828911]
  • Marika T Granfors, Janne T Backman, Mikko Neuvonen, Pertti J Neuvonen. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clinical pharmacology and therapeutics. 2004 Dec; 76(6):598-606. doi: 10.1016/j.clpt.2004.08.018. [PMID: 15592331]
  • Marika T Granfors, Janne T Backman, Mikko Neuvonen, Jouni Ahonen, Pertti J Neuvonen. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clinical pharmacology and therapeutics. 2004 Apr; 75(4):331-41. doi: 10.1016/j.clpt.2003.12.005. [PMID: 15060511]
  • Jaeick Lee, Jae Hong Seo, Dong-Hyun Kim. Determination of tizanidine in human plasma by gas chromatography-mass spectrometry. The Analyst. 2002 Jul; 127(7):917-20. doi: 10.1039/b202271k. [PMID: 12173650]
  • A Pinelli, S Trivulzio, R Spezia. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats. Drug and alcohol dependence. 1998 Mar; 50(1):81-8. doi: 10.1016/s0376-8716(98)00010-6. [PMID: 9589275]
  • P W Nance, W A Sheremata, S G Lynch, T Vollmer, S Hudson, G S Francis, P O'Connor, J A Cohen, R T Schapiro, R Whitham, M K Mass, J W Lindsey, K Shellenberger. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Archives of neurology. 1997 Jun; 54(6):731-6. doi: 10.1001/archneur.1997.00550180049011. [PMID: 9193208]
  • A J Wagstaff, H M Bryson. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar; 53(3):435-52. doi: 10.2165/00003495-199753030-00007. [PMID: 9074844]
  • M Emre, G C Leslie, C Muir, N J Part, R Pokorny, R C Roberts. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). Journal of neurology, neurosurgery, and psychiatry. 1994 Nov; 57(11):1355-9. doi: 10.1136/jnnp.57.11.1355. [PMID: 7964811]
  • R C Roberts, N J Part, R Pokorny, C Muir, G C Leslie, M Emre. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology. 1994 Nov; 44(11 Suppl 9):S29-31. doi: NULL. [PMID: 7970008]
  • I Muramatsu, S Kigoshi. Tizanidine may discriminate between imidazoline-receptors and alpha 2-adrenoceptors. Japanese journal of pharmacology. 1992 Aug; 59(4):457-9. doi: 10.1254/jjp.59.457. [PMID: 1331591]
  • T Shimomura, E Awaki, H Kowa, K Takahashi. Treatment of tension-type headache with tizanidine hydrochloride: its efficacy and relationship to the plasma MHPG concentration. Headache. 1991 Oct; 31(9):601-4. doi: 10.1111/j.1526-4610.1991.hed3109601.x. [PMID: 1774177]
  • P Koch, D R Hirst, B R von Wartburg. Biological fate of sirdalud in animals and man. Xenobiotica; the fate of foreign compounds in biological systems. 1989 Nov; 19(11):1255-65. doi: 10.3109/00498258909043177. [PMID: 2618078]
  • C J Mathias, J Luckitt, P Desai, H Baker, W el Masri, H L Frankel. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. Journal of rehabilitation research and development. 1989; 26(4):9-16. doi: . [PMID: 2600869]
  • F L Tse, J M Jaffe, S Bhuta. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundamental & clinical pharmacology. 1987; 1(6):479-88. doi: 10.1111/j.1472-8206.1987.tb00581.x. [PMID: 3447935]
  • V Heazlewood, P Symoniw, P Maruff, M J Eadie. Tizanidine--initial pharmacokinetic studies in patients with spasticity. European journal of clinical pharmacology. 1983; 25(1):65-7. doi: 10.1007/bf00544016. [PMID: 6617726]
  • A C Sayers, H R Bürki, E Eichenberger. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent. Arzneimittel-Forschung. 1980; 30(5):793-803. doi: . [PMID: 7190422]